While they help prevent autoimmunity, many cancers exploit this pathway to evade immune detection. PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune ...

在当今肿瘤治疗领域，新型抗肿瘤药物中的「靶向治疗药物」与「免疫检查点抑制剂」堪称闪亮双子星。靶向治疗药物需通过基因检测明确敏感靶点，从而实现精准施治；而免疫检查点抑制剂虽尚未形成统一的生物标志物评估标准，但 PD-L1 高表达通常预示着更优的治疗反应，可作为免疫治疗的重要参考指标。那么，当 EGFR ...

为评估 PD-1/L1 免疫检查点抑制剂（ICIs）对 KRAS 突变晚期非小细胞肺癌疗效，研究发现其一线治疗 PFS 更优，且有预测标志物。 肺癌作为全球发病率和死亡率最高的恶性肿瘤之一，其中非小细胞肺癌（NSCLC）占比 85-90%。KRAS（Kirsten 大鼠肉瘤病毒癌基因同源物 ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

In the study, "Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumors ... the efficacy of existing immune checkpoint inhibitors, offering new hope for patients ...

"Our findings indicate that while checkpoint inhibitors boost anti-cancer ... rare cases of genetic deficiency of PD-1, or its binding partner PD-L1, as well as animal models lacking PD-1 signaling.

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect ...

CTLA4 Inhibitors Market forecast to 2035 covers market size, key trends, competitive landscape, and growth opportunities in cancer immunotherapy and autoimmune diseases.

Detailed price information for Sensei Biotherapeutics Inc (SNSE-Q) from The Globe and Mail including charting and trades.